Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis

Darius Armstrong-James1,13, Jonathan Youngs2, Tihana Bicanic2, Alireza Abdolrasouli3, David W. Denning 4, Elizabeth Johnson5, Varun Mehra6, Tony Pagliuca6, Brijesh Patel7, Johanna Rhodes8, Silke Schelenz9, Anand Shah8,10, Frank L. van de Veerdonk11, Paul E. Verweij11, P. Lewis White12 and Matthew C. Fisher8,13

Affiliations: 1Dept of Infectious Diseases, Imperial College London, London, UK. 2Institute of Infection and Immunity, St George’s University of London, London, UK. 3Dept of Medical Microbiology, North West London Pathology, Imperial College Healthcare NHS Trust, London, UK. 4Faculty of Biology, Medicine and Health, The University of Manchester, National Aspergillosis Centre, Wythenshawe Hospital and Manchester Academic Health Science Centre, Manchester, UK. 5Mycology Reference Laboratory, Public Health England National Infection Service, Bristol, UK. 6Dept of Haematological Medicine, Kings College Hospital NHS Foundation Trust, London, UK. 7Dept of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. 8MRC Center for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK. 9Infection Sciences, Kings College Hospital NHS Foundation Trust, London, UK. 10Royal Brompton and Harefield NHS Foundation Trust, London, UK. 11Dept of Medical Microbiology and Centre of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Centre, Nijmegen, The Netherlands. 12Mycology Reference Laboratory, Public Health Wales Microbiology Cardiff, Cardiff, UK. 13D. Armstrong-James and Matthew C. Fisher contributed equally to this article as lead authors and supervised the work.

Correspondence: Darius Armstrong-James, Imperial College London, Dept of Infectious Diseases, Flowers Building, London, SW7 2AZ, UK. E-mail: d.armstrong@imperial.ac.uk

@ERSpublications
Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections https://bit.ly/3feuGsQ

Cite this article as: Armstrong-James D, Youngs J, Bicanic T, et al. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. *Eur Respir J* 2020; 56: 2002554 [https://doi.org/10.1183/13993003.02554-2020].

This single-page version can be shared freely online.

The coronavirus disease 2019 (COVID-19) virus caused a wide spectrum of disease in healthy individuals, as well as those with common comorbidities [1]. Severe COVID-19 is characterised by acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis, treatment of which may require mechanical ventilation or extracorporeal membrane oxygenation [2]. Clinicians are alert to the possibility of bacterial co-infection as a complication of lower respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in particular COVID-19 associated pulmonary aspergillosis (CAPA), remains underappreciated.

Copyright ©ERS 2020. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.